MK-0557

DB12168InvestigationalSmall molecule

MK0557 has been investigated for the treatment of Schizophrenia and Paranoid Schizophrenia.

Mechanism: Pharmacologically active on Neuropeptide Y receptor type 5
Curator reviewed
Formula / weight: C₂₂H₁₉FN₄O₃ · 406.417 g/mol (avg)
Code names: MK0557

Resolves to

Compound

Structure

InChIKeyRMYZIRFUCOMQRH-CAJLXGCNSA-NSMILESFC1=C(C=CC=C1)N1C=CC(NC(=O)[C@H]2CC[C@@]3(CC2)OC(=O)C2=C3C=NC=C2)=N1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-0557, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.